These results clearly indicate that similar to other tumor cells, EZH2 inhibition in MPM cells might enhance the recruitment of Th1 (CXCL10, CXCL11) but not of Th2 (CCL17, CCL22) cells. The gene discussed is CCL17; the disease is neoplasm.